Monthly Archives: July 2021

Learn how to remove unwanted fat with procedures beyond liposuction – ABC 4

Posted: July 21, 2021 at 2:43 am

Dr. Bill Cimikoski, Medical Director of Utah Stem Cellsjoined Surae on The Daily Dish to discuss the BodyTite and Facetite procedures. He tells Surae that these procedures are excellent for getting rid of unwanted fat, while at the same time shrink wrapping the skin so that any loose skin is simultaneously tightened at the same time.

For some individuals, there may only be minimal (or none at all) fat to extract and it might be only necessary to tighten the skin. Depending on the area Utah Stem Cells are treating, they often see that in some individuals, there isnt really any fat to speak of and their patients are just looking for skin tightening and this is an excellent way to achieve that goal!

Unfortunately, on the other hand, some patients do have a large amount of fat in certain areas and then this device is also accompanied by liposuction. This is where they can suck the fat in addition to tightening the loose skin at the same time.This procedure is called Radio Frequency assisted Liposuction. At Utah Stem Cells they also offer High Definition Radio Frequency assisted liposuction to sculpt abs.

They offer many different treatments for different areas of the body, including the following:

All procedures are in-office and with only small holes or needle punctures, which heal completely without scarring. There is no need for general anesthesia and all are completed with lidocaine fluid although they do offer nitrous oxide, ketamine, and other methods to keep people comfortable and less anxious.

As a special gift, anyone who calls in after viewing The Daily Dish today will be entitled to $200 off any procedure.

To find out more about how Dr. Bill Cimikoski and Utah Stem Cells can help you, visit their website or you can give them a call at Phone number: (801) 999-4860

This article contains sponsored content.

Continue reading here:
Learn how to remove unwanted fat with procedures beyond liposuction - ABC 4

Posted in Utah Stem Cells | Comments Off on Learn how to remove unwanted fat with procedures beyond liposuction – ABC 4

John Theurer Cancer Center Investigators Participated in ZUMA-7 Study Showing Value of CAR T-Cell Therapy as Second-Line Treatment for Relapsed Large…

Posted: July 21, 2021 at 2:42 am

Newswise HACKENSACK, N.J. (DATE TK) A new study has found that using CAR T-cell therapy as the second line of treatment for diffusing large B-cell lymphoma (DLBCL) that has returned or continued to grow after initial treatment was more effective than the standard second-line regimen of care for improving event-free survival (EFS / defined as disease progression, needing to start a new lymphoma treatment, or death from any cause). Investigators from Hackensack Meridian/Hackensack University Medical Centers John Theurer Cancer Center (JTCC), a part of Georgetown Lombardi Comprehensive Cancer Center, participated in the multicenter international study, called ZUMA-7.

With a median follow-up of two years, the study showed that patients with DLBCL who received a one-time infusion of axicabtagene ciloleucel (Yescarta) experienced a 60% improvement in EFS compared with patients who received standard care with chemotherapy and autologous stem cell transplantation. Patients in the CAR T-cell therapy group also experienced a better overall response rate. The study is continuing with additional follow-up to assess the effect of the treatments on overall survival and other key endpoints.

Axicabtagene ciloleucel is currently approved by the U.S. Food and Drug Administration for the treatment of large B-cell lymphoma that relapses after or fails to respond to at least two prior regimens of therapy.

"This is a very exciting paradigm shift for the treatment of large B-cell lymphoma," explained hematologist-oncologist Lori Leslie, M.D., who led JTCC's participation in the ZUMA-7 study. "A 60% improvement in event-free survival is more dramatic than one would anticipate and suggests that early relapsers and some patients at high risk of relapse after initial treatment may benefit from proceeding directly to CAR T-cell therapy."

About 40% of patients with DLBCL will need a second regimen of treatment.

CAR T-cell therapy is a form of treatment which involves removing white blood cells called T cells from the patient, modifying them in the laboratory to train them to see a protein (called CD19) on lymphoma cells, and then multiplying them to much larger numbers. When given back to the patient intravenously, they expand further, ideally identifying and killing cancer cells anywhere in the body.CAR T-cell therapy is a form of immunotherapy and has been called a "living therapy" because the newly trained T cells continue to find and destroy cancer cells in the body.

As a leader in CAR T therapy, we are proud to be a part of this new development in research that will continue to reshape the landscape of relapsed/refractory aggressive lymphoma who fail standard regimens of chemoimmunotherapy, said Andre Goy, M.D., M.S., chairman and executive director of John Theurer Cancer Center.

The ZUMA-7 study began in 2017 and includes 359 patients with DLBCL at 77 medical centers around the world, 30% of whom were 65 years or older. Side effects observed in the study were consistent with or even more favorable than the safety profile previously established for axicabtagene ciloleucel. The use of CAR T-cell therapy as second-line treatment did not result in any new safety concerns. Yescarta has been instrumental in transforming outcomes for DLBCL patients in third line setting. It is likely the paradigm will continue to shift towards earlier timing in patients with early failures.

"The contributions that the John Theurer Cancer Center made toward identifying a better therapy for the research and treatment of lymphoma further establishes its position as a leading center, " said Ihor Sawczuk, MD, FACS, president, Northern Region, and chief research officer, Hackensack Meridian Health. "Hackensack Meridian Health is proud to have been involved in this pivotal study."

"We are dedicated to continuing to provide the latest research-based treatments to the members of our communities," added Mark D. Sparta, FACHE, president and chief hospital executive, Hackensack University Medical Center and executive vice president of Population Health, Hackensack MeridianHealth. "John Theurer Cancer Center was the first center in New Jersey to be certified to offer CAR T-cell therapy and was active in research assessing its use long before its first FDA approval. We are very excited to see these promising results, which show how this powerful immunotherapy may benefit more people."

ABOUT JOHN THEURER CANCER CENTER HACKENSACK UNIVERSITY MEDICAL CENTER

John Theurer Cancer Center at Hackensack University Medical Center is New Jersey's best cancer center, as recognized by U.S. News & World Report. As a premier cancer center in the State we are also the largest and most comprehensive center dedicated to diagnosis, treatment, management, research, screening, and preventive care as well as survivorship of patients with all types of cancers. The 16 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. Each year, more people in the New Jersey/New York metropolitan area turn to John Theurer Cancer Center for cancer care than to any other facility in New Jersey. John Theurer Cancer Center is part of the Georgetown Lombardi Comprehensive Cancer Center, an NCI designated comprehensive cancer center. Housed within a 775-bed not-for-profit teaching, tertiary care, and research hospital, John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of aftercare services that distinguish John Theurer Cancer Center from other facilities. For additional information, please visit http://www.jtcancercenter.org

###

Read more from the original source:
John Theurer Cancer Center Investigators Participated in ZUMA-7 Study Showing Value of CAR T-Cell Therapy as Second-Line Treatment for Relapsed Large...

Posted in New Jersey Stem Cells | Comments Off on John Theurer Cancer Center Investigators Participated in ZUMA-7 Study Showing Value of CAR T-Cell Therapy as Second-Line Treatment for Relapsed Large…

ExoFlo From Direct Biologics Fulfills Urgent Medical Need in COVID-19 Treatment – PRNewswire

Posted: July 21, 2021 at 2:42 am

Medical professionals report dramatic and consistent success in treating patients gravely ill with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS)

AUSTIN, Texas, July 20, 2021 /PRNewswire/ -- As intensive care units across the country fill to capacity, hospital beds are in dangerously short supply, and deaths from COVID-19 continue to spike, doctors from medical centers coast to coast are reporting on the remarkable healing properties of ExoFlo, an innovative life-saving therapy that leverages the anti-inflammatory and regenerative effects of bone-marrow derived mesenchymal stem cells, when used on their most seriously ill COVID-19 patients. The physicians note that utilizing ExoFlo, administered as a single IV infusion, is safe and efficacious and is saving lives on a consistent basis.

One of the product's earliest advocates, Dr. Vik Sengupta of New York, credits ExoFlo with saving his own life. He has since used it on many critically ill patients, eagerly shared it with colleagues, and coauthored, with his wife, Dr. Sascha Sengupta, a clinical safety trial conducted at Christ Hospital in Jersey City, N.J. as part of the therapy's FDA approval process. The safety data from this study has since set the stage for the FDA approval of ExoFlo for an Investigational New Drug (IND) application for COVID-19.

"The most common cause of death among critically ill COVID-19 patients is acute respiratory distress symptom, or ARDS, in which the lungs are badly damaged, scarred and fill with fluid," explained Dr. Sengupta. "This is essentially a result of the body reacting to a threat by overproducing cytokines and other mediators of inflammation that cause damage to the lungs and other tissues in the body in a phenomenon commonly known as the 'cytokine storm.'

"ExoFlo does two important things: it remediates the inflammation almost immediately by delivering miRNA that stop the inflammatory cascade, and it delivers growth factors that promote the regeneration of healthy lung tissue for a much speedier recovery."

ExoFlo is manufactured by Direct Biologics, a market-leading cGMP manufacturer of regenerative medical products based in Austin, Texas. ExoFlo has amazed doctors with its ability to fill an unmet but urgent medical need, saving the lives of patients experiencing COVID-19- associated Acute Respiratory Distress Syndrome. Time and again, patients were able to be discharged and returned to their families rather than deteriorating to an irreversible state.

"This product could not have come at a better time," noted Dr. Angel Lazo Jr. of New Jersey. "This product also opens the door to medical solutions forpost-pandemic concerns, when there will be an urgent need to address COVID-19 survivors suffering from Post-Acute COVID Syndrome (PACS), often referred to as long-hauler COVID, and to remediate compromised immune systems and likely lasting pulmonary scarring."

Dr. Sengupta recalls his first experience with ExoFlo: "We were all exhausted, working multiple shifts during the worst of the early days of the epidemic when the New York area was hit so hard. A friend asked me if I could help her elderly parents, both in their 80s and both very ill with COVID-19.The wife had been admitted to the hospital, and unfortunately, despite our best efforts, the hospital administration refused us permission to treat her with ExoFlo.The husband, who had been declining quickly and suffered from a fever, hypoxia, delirium, diarrhea, no sense of taste, and lack of appetite, became the first documented patient in medical history to be administered an exosome-based treatment for critical respiratory illness. He received ExoFlo at home without any adverse reactions and was out of bed and singing arias within two days.Sadly, and unbeknownst to him, his wife had died in the hospital."

This was a dramatic and eye-opening experience. "When I myself fell victim to COVID, I became seriously ill very fast," noted Dr. Sengupta. "I awoke in the middle of the night, struggling to breath and sinking into delirium, and checked my O2sat, immediately realizing I was going into respiratory failure. I called my wife.She left her shift at the hospital, rushed home, and administered ExoFlo. Within 24 hours my supplemental oxygenation requirement, fever, and respiratory symptoms significantly improved. And within five days of that single dose, I was almost fully recovered from the acute infection. I firmly believe that ExoFlo saved my life."

As word spreads within the medical community, increasing numbers of doctors have been astounded by the efficacy and safety of ExoFlo. Among those who have gone on record singing its praises are Dr. Iman Bar of Newport Beach, Calif., and Dr. Jack Mann of Flushing, N.Y.

"The COVID-19 pandemic has presented doctors with a heartbreaking learning curve," said Dr. Sengupta, who has since become Direct Biologic's chief medical officer. "For months we had no choice but to stand by while patients died despite our best efforts to save them. It's an incredible relief now to have ExoFlo in our arsenal of treatments."

ExoFlo is a biopharmaceutical grade regenerative medicine product that represents a meaningful therapy in the fight against the deadly lung inflammation caused by the COVID-19 virus. The new investigational drug uses extracellular vesicles and growth factor proteins isolated from human bone marrow mesenchymal stem cells (MSCs) to reduce inflammation and direct cellular communication capable of strengthening the body's defenses and advancing its healing processes.

ExoFlo is currently in a Phase II clinical trial that expands knowledge gleaned from a prospective, open-label study in which 17 out of 24 patients demonstrated resolution of their ARDS, exhibiting biomarker and oxygenation improvements within 48-72 hours following treatment with a single 15mL intravenous dose of ExoFlo. Since receiving FDA approval of an expanded access protocol in October 2020, ExoFlo is also being utilized by physicians around the country as part of single patient emergency or compassionate use protocol, commonly referred to as eIND.

About Direct Biologics

Direct Biologics, LLC, is headquartered in Austin, Texas, with a recently expanded R&D facility located at the University of California, and an Operations and Order Fulfillment Center located in St. Louis, Missouri. Direct Biologics is a market-leading innovator and cGMP manufacturer of regenerative medical products, including a robust line of extracellular vesicle-based biological products. The company was created to expand the science of regenerative healing by delivering cutting-edge biologic technologies. Direct Biologics' management team holds extensive collective experience in biologics research, development, and commercialization, making the company a leader in the evolving, next generation segment of the biotherapeutics industry. Direct Biologics is dedicated to pursuing additional clinical applications of its extracellular vesicle biologic products through the FDA's investigational new drug application process.

For more information visithttp://www.directbiologics.com.

CONTACT INFORMATION:Tiffany Kayar[emailprotected]

Related Images

direct-biologics-logo.png Direct Biologics Logo

Homepage

SOURCE Direct Biologics

Read the original:
ExoFlo From Direct Biologics Fulfills Urgent Medical Need in COVID-19 Treatment - PRNewswire

Posted in New Jersey Stem Cells | Comments Off on ExoFlo From Direct Biologics Fulfills Urgent Medical Need in COVID-19 Treatment – PRNewswire

GXGX Merger: The SPAC News That Has GXGX Stock Soaring – InvestorPlace

Posted: July 21, 2021 at 2:42 am

A new SPAC (special purpose acquisition company) play is catching the eyes of investors today. The second half of 2021 looks like it will be filled with hot initial public offerings (IPOs) and SPAC mergers like Robinhood andAurora. Now, anew play will be blending the hype of a new public offering with the pandemic-fed hype toward biotech plays. GX Acquisition (NASDAQ:GXGX) is announcing today their plans to make an attractive biotech outfit public in the newest GXGX merger news.

Source: Shutterstock

GX Acquisition is the newest shell company to take a private entity to market. Today, they are making known their selection in Celularity. Celularity is a New Jersey-based biotechnology outfit that specializes in the treatment of cancer and degenerative diseases. The company takes on these persistent and devastating illnesses by harnessing the power of placenta-based stem cells. Most recently, the company launched its T-cell program, in which it is developing treatments against tumorous growths using mutated placental cells.

Today, GX is happily announcing the closure of its merger with Celularity. The transaction is already paying off well for Celularity; proceeds from the transaction total a cool $138 million. Investors can look forward to Mondays trading session, as Celularity will be taking over on the Nasdaq with the ticker symbol CELU. In the meantime, the GXGX merger is elevating the SPACs stock value.

CEO of GX Dean Kehler is speaking excitedly about Celularitys prospects after seeing a listing. He says the listing will enable Celularity to continue to leverage the companys commercial and clinical stage assets to treat diseases of high unmet need.

Analysts are clamoring ahead of the CELU listing, likeMarket Realist, which called the stem-cell play risky but attractive. Perhaps one of the most appealing aspects of Celularity is its recent partnership with Peter ThielsPalantir Technologies (NYSE:PLTR). The partnership is providing Celularity with fresh cash for furthering its resources. It also ties Celularity to one of the most attractive tech plays on the market right now.

GXGX stock is soaring ahead of the news. The stock is seeing gains of over 34% since the news broke. 15 million shares are exchanging hands today as well, high above GXGXs daily average volume of 313,000.

On the date of publication, Brenden Rearickdid not have (either directly or indirectly) any positions in the securities mentioned in this article.The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines.

The rest is here:
GXGX Merger: The SPAC News That Has GXGX Stock Soaring - InvestorPlace

Posted in New Jersey Stem Cells | Comments Off on GXGX Merger: The SPAC News That Has GXGX Stock Soaring – InvestorPlace

Five minutes with Rafe Johnson – 2021 – Articles – Transform magazine

Posted: July 21, 2021 at 2:41 am

How did you begin working on the development and ideation of a bionic heart?

I was approached by The Science Museum of Minnesota to design and develop experiences for an upcoming exhibition based around transhumanism, the process of humans merging with technology. One of these projects was to create a 3D hologram animation that presents a series of futuristic bionic organs using the peppers ghost concept which presents the hologram. What I found particularly interesting, and challenging was conceptualising a bionic heart through digital design. I was tasked with designing something that was both visually compelling and yet believable, the design concept had to be to be physiologically so that if it was used to design the physical product it could be implanted into someone, connecting the tubing to their arteries.

The goal of this exhibition, which runs parallel with my own goals, is to introduce the public to the world of human enhancement in an exciting and informative way, and what is more engaging than a holographic image of futuristic implants? There is plenty of science fiction that considers bionic bodies, but they tend to paint a dystopian world that makes us fear technological progress rather than welcome it; I believe its essential we paint an exciting picture of the future in which the capabilities of humans are vastly expanded, and I feel this exhibition portrays that perfectly.

What will designing in AR look like ten years away?

Whilst the fundamental process of designing is unlikely to change, the tools we use during the process certainly will. Augmented reality (AR) is one of the most interesting and exciting tools that can be used for this. As computers continue to reduce in size and increase in power we will see AR devices like the Microsoft Hololens reduce in size from bulky headsets to glasses to contact lenses and eventually brain implants. All aspects of the design process from research to prototyping will become faster, more streamlined and more connected, with areas of design most affected being concepting/prototyping and collaboration. We will be able to design, prototype, package and release our creations on one single platform, just as we often do with computers now. Our freedom to design where and when will be improved, despite your location; and our ability to collaborate will greatly increase as you'll be able to sync with collaborators anywhere in the world and instantly feel like you are in the same room as them. Discussing changes to your car design that's represented digitally in front of you, quickly making tweaks to the cars surfacing or perhaps the paint finish. At Seymourpowell we are already utilizing this technology, for example, when we were building the interior of Virgin Galactic's spaceship, I could be in my home in VR taking in feedback from a 3D avatar representation of my colleagues as we analyzed the inside of the ship. This allowed me to test and identify issues far more closely and talk to top designers around the UK.

What role does extended reality (XR) play in the world of transhumanism?

XR will play a very prominent role in the world of transhumanism, perhaps one of the most important roles. It's worth asking what reality is at this point. Reality in its simplest form is the sum or aggregate of all that is real or existent within a system. Our experience of reality is largely defined by our senses. If our sensory organs and brains can be adjusted, then so can our reality. In decades to come we may be able to experience things we cant yet comprehend. Neuroscientist David Eagleman is already exploring sensory substitution, creating a vest that converts audio data to vibrations, allowing users to feel sounds. His findings show that after some time users who have lost their hearing can start to understand what others are saying through these vibrations. As AR becomes more integrated into our lives, the more we will rely on extended reality technologies, just as we rely so heavily on our mobile phones now. Elon Musk argues that our attachment to mobile phones already makes us a form of early cyborg, imagine trying to go about your daily life without using a mobile phone. Whilst some voice understandable concern about having technologies so closely connected to our bodies, there are huge benefits, especially in the medical world. We will develop a much closer understanding and level of control of our own bodies and XR will be our primary way of interfacing with this.

What is the future of neural implants and how is the design process defining this?

A neural implant is a piece of technology implanted into the brain. Currently they're in the very early stages, however, many neuroscientists and tech leaders are working on prototypes and testing. It's likely the first brain implants will be used for medical purposes like repairing eyesight or reversing effects of other neural based diseases. The technology will inevitably move into the world of brain enhancement, for example a brain computer interface (BCI), which does exactly what youd think, connects your brain directly to a computer. Once we step into the world of altering and enhancing our brains, we really begin to consider the reality of turning ourselves into super humans, science fiction no more! Imagine a world in which brain enhanced humans can learn languages overnight or perhaps communicate telepathically. It will eventually become as easy as closing your eyes and plugging into the virtual world. As with all technologies and inventions, neural implants are driven and developed by the design process. It's the designers job to plan and direct the development of these technologies and ensure the best possible outcome. As with any design project, the prototyping phase is critical in testing and understanding which paths to take, and to help avoid any possible detrimental outcomes.

See the rest here:
Five minutes with Rafe Johnson - 2021 - Articles - Transform magazine

Posted in Transhumanism | Comments Off on Five minutes with Rafe Johnson – 2021 – Articles – Transform magazine

How Many Milligrams Of Testosterone Do Men Naturally …

Posted: July 21, 2021 at 2:37 am

How many milligrams of Testosterone do men naturally produce?

3-10 milligrams per day, with the average being 6-7 milligrams per day.

When bodybuilders refer to Testosterone Replacement Therapy (TRT) dosages theyll often state that 200 milligrams is a therapeutic dosage.

This is typically not a therapeutic dosage at all, and is more like a small supraphysiological cycle being used year round.

A therapeutic dosage of Testosterone is a dosage that would bring serum Total and Free Testosterone levels in the blood up to what you would produce naturally if you werent hypogonadal.

Delving into the clinical data, we can see that the true milligram equivalent is actually far less than that.

Before delving in deeper, keep in mind that ester weight and the milligram amount per milliliter stated on the vial of your prescription doesn't necessarily equate to how many milligrams of Testosterone per milliliter your product truly contains. Let me elaborate on that.

Testosterone is the principal circulating androgen.

In men, it is secreted primarily by the Leydig cells in the testes at a daily production of about 6-7 mg [R].

Other clinical data corroborates this as well.

A more broad and accurate range is 3-10 mg per day [R], but in general, the average daily production is approximately 6-7 mg per day in healthy men.

The difference between 3 mg per day and 10 mg per day is massive, as you would logically conclude.

However, this is not reflected in the therapeutic reference ranges you will see in your blood work.

Depending on the lab, the healthy range of natural Testosterone production could be as low as 240 ng/dL on the bottom, and 1000 ng/dL on the high end.

Some labs are even worse.

It doesnt take a rocket scientist to realize that a Testosterone level 4x higher will not equate to the same quality of life, muscle building potential, etc.

However, 90% of doctors still are so far behind the curve that they truly believe that a 250 ng/dL Testosterone level is just as good as a 1000 ng/dL Testosterone level.

Based on the daily average production in milligrams, we can calculate that weekly the average healthy male produces between 42 to 49 mg per week.

A ton of men using 200 mg per week probably think that number is far too low and isnt accurate.

However, what a lot of guys don't consider is that the ester itself takes up a significant portion of the milligram content per milliliter.

After administering Testosterone, your body has to cleave the ester from the molecule to free up the Testosterone to actually be bioavailable in the body, and that ester accounts for a significant portion of that milligram/milliliter amount.

The only exception to this is Testosterone Base and Testosterone Suspension, which are just straight up Testosterone products with no ester attached, but you would never get a prescription for that as the half-life is so short it would require multiple administrations per day.

The Cypionate ester has a high molecular weight and accounts for 30% of the milligram total stated on a TRT prescription.

For example, if your TRT prescription was 200 mg of Testosterone Cypionate every week, despite the vial being labeled as 200 mg/ml, the Cypionate esters molecular weight takes up 30% of that mg content, and cleaving the ester from the Testosterone molecule in the body leaves only 140 mg/ml, which is 70% of the stated label dosage.

There are vastly different perspectives on hormone levels in the TRT community and the bodybuilding community.

There are many men (mostly bodybuilders) who believe that 200 mg per week is the bare minimum for high-end TRT, and dosages of 250 mg or even 300 mg per week are justified as within the realm of natural production still.

There are doctors who will corroborate this too, which to me is pretty baffling.

Very, very seldom does somebody actually need 200 mg a week to maintain the equivalent of healthy endogenous production.

Usually, those guys are essentially running a cycle year-round.

This is something Ive been saying for a while now, as I used to actually believe that 200 mg per week was therapeutic (until I started really monitoring my blood work closely).

My TRT is currently 125 mg per week, and even that is pushing into supraphysiological territory when you actually split that shot into seven micro shots to keep more stable blood serum concentrations.

Splitting a large dosage/administration of 125 mg per week into 7 administrations/micro-doses of 18 mg per day increases Free Testosterone more relative to a large weekly dosage, decreases the amount of aromatization to Estrogen occurring in the body, and maintains more stable Testosterone blood serum concentrations.

Often times, doctors will prescribe their patients 100 200 mg of Testosterone Cypionate every 7-10 days, and then advise them to administer it in one giant dosage once per week, or even once every 2 weeks.

This is insane and reflects on how completely inept the majority of physicians are when it comes to hormone management.

When you administer yourself with a large dosage at once, you spike your Testosterone levels to supraphysiological levels, often 2x or even 3x as high as they should be for a few days, which obviously has an equivalent amount of aromatization occurring in parallel to this.

Following this, levels slowly crash down as hormone levels decline in the body, and often times patients will fall back down to the low end of the reference range while waiting for their next shot.

The end result is a constant roller coaster of fluctuating Testosterone levels going from way too high, to way too low, over and over again, with far too much Estrogen aromatization occurring, resulting in completely unnecessary side effects.

These side effects often then need to be mitigated with an Aromatase Inhibitor, which doctors know even less about how to prescribe and mange correctly, and will often crash their patients E2 levels into the ground and leave them feeling like complete trash and ruining their lipids.

AIs are not something you want to be on long term as they are not healthy, and E2 management can be done via lifestyle and diet changes more often than not in the context of therapeutic TRT.

There are constant arguments about what the optimal replacement dose of Testosterone is.

There's a small camp of guys who believe that 10 milligrams of Testosterone Propionate per day is ideal for most men, and I'm inclined to agree with them far more than the guys who believe that dosages as high as 200 mg per week are necessary.

This will of course vary depending on a variety of factors, but typically 10 mg of Testosterone Propionate per day will put an individual at top end of the Testosterone therapeutic range.

I find that when men talk about ideal dosages being closer to 125 150 200 mg per week, the ester weight often isn't taken into account (Cypionate, Enanthate, Propionate, etc. all have different molecular weights), and they are often individuals who administer large dosages at once, let their levels spike way above the therapeutic limit up to supraphysiological levels for a few days, and slowly crash underneath that until their next shot.

If you get your blood drawn during a trough and the results show that you have a 850 ng/dL Testosterone level, you may not be accounting for the fact that right after you administered your fat weekly (or even bi-weekly) dosage, your levels probably skyrocketed upwards of 1500 ng/dL.

I found this statistic very interesting as 50 milligrams a week really is not much whatsoever in contrast to what most guys are injecting weekly believing they are just replacing their natural production.

There are a lot of massive bodybuilders, including IFBB pros, who maintain massive physiques in the off-season and in retirement with just 200 mg of Testosterone per week.

They're able to maintain physiques that are blatantly not maintainable naturally.

If top bodybuilders who are pros at 240 pounds plus are maintaining those physiques with just 200 mg per week, its pretty transparent that the 200 mg per week dosage is actually more than the therapeutic amount in most situations, and the clinical data backs this up.

Personally, I used to believe I needed 200 mg per week to maintain my physique, and I was SO wrong.

200 mg per week for most individuals is the equivalent of running a cycle year round, and certainly is not therapeutic in any capacity.

There are caveats to this, with SHBG, ester choice, body composition, diet, lifestyle factors, and many other things playing a significant role in how much Testosterone actually becomes usable in the body, consequently influencing how large of a dosage an individual would need to achieve healthy Free Testosterone levels.

But in general, true therapeutic TRT would be as simple as replicating the natural daily production of 6-7 mg with an exogenous source after factoring in the ester weight.

P.S. I do all of my daily TRT injections with an insulin pin now in my glutes and ventro glutes.

With such a low volume of daily oil, its something I can get away with daily without creating a lump of oil that doesnt absorb properly, which would occur if you tried to jab a large amount of oil too shallowly with a short needle.

No more harpoons for me.

Related

Read more:
How Many Milligrams Of Testosterone Do Men Naturally ...

Posted in Testosterone Shots | Comments Off on How Many Milligrams Of Testosterone Do Men Naturally …

How Humans Really Burn Calories And What That Means For Losing Weight : Shots – Health News – NPR

Posted: July 21, 2021 at 2:37 am

Intense physical activity may not be as helpful in losing weight as you may hope. Catherine Falls/Getty Images hide caption

Intense physical activity may not be as helpful in losing weight as you may hope.

It's an eternal question: What diet is best for weight loss? Or, what should we eat (or avoid) to stay healthy?

Devotees of paleo or keto will talk your ear off about why their diet is the most sensible. People choosing vegan diets (no animal products, including dairy) make a compelling case for both personal and global health.

Herman Pontzer, an evolutionary anthropologist at Duke University, argues that human metabolism has evolved to the point where how we eat and expend our calories is more important than all of our collective obsession with what to eat.

In his new book, Burn: New Research Blows the Lid Off How We Really Burn Calories, Stay Healthy and Lose Weight, Pontzer breaks down the science of metabolism and shares tales from his work studying caloric expenditure among hunter-gatherer societies.

One of the most startling findings is the notion of constrained daily energy expenditure. This is the idea that the human metabolism adapts to our activity levels to keep our daily calorie burn in a surprisingly narrow range no matter how hard you work out. But don't let that depressing fact hold you back from the gym it's crucial that you still get daily exercise for weight maintenance and overall health.

This interview with Pontzer is adapted from an interview for Public Radio Tulsa's Medical Monday program and has been edited for length and clarity.

In your book you debunk the common metaphor we use for caloric expenditure an engine or a machine. You say it would be more accurate to compare it to running a business. Why is that?

The engine view gets a few things right. We put fuel into our bodies in the form of food. And we do burn it off in all the tasks that our body does, the way that an engine burns fuel.

But an engine, like the engine in your car, doesn't get to decide how it burns the fuel. A car's energy burn is all about how hard you step on the gas pedal. Your body isn't like that. Your body is more like a business, as it has an overall goal like any business does. The overall goal of your body is to survive and reproduce, because that's what every organism has evolved to do. But there are many parts and pieces and departments that are in the service of that overall goal.

In a business you have finance, sales, human resources and security and everything else. It's the same with your body. You've got all these different organ systems that all work together. And like a business, when income is low, you can juggle things around. So you spend less on this or that task. And when things are good, you can ramp up the energy that you spend on different tasks. And so that kind of juggling or prioritization that businesses do is the same that your body can do with how it spends calories.

One fallacy with the engine model of calorie burning is we think, OK, I've got to burn more calories than I take in, either by eating less or exercising more or both. But as you point out, the metabolism adjusts, and it becomes harder to lose weight. So even though exercise isn't really a great weight-loss strategy, it's still very important for your overall health, right?

That's exactly right. If you're more physically active, eventually you don't burn more calories a day, but you change the way your calories are spent. If you spend your calories on exercise, what that means is you're spending fewer calories on other tasks.

And for most of us, that's a really good thing, because if we spend less energy, for example, on inflammation, we reduce our inflammation levels. If we spend less energy on stress reactivity, for example, our cortisol levels don't go up as high and our adrenaline levels don't go up as high, we achieve lower levels of stress response. And it seems that that exercise might also help keep testosterone for men or estrogen levels for women at a slightly healthier level. So that adjustment, that metabolic adjustment that we make is one of the reasons exercise is so good for us.

You've done extensive research with modern-day hunter-gatherers, like the Hadza people of Tanzania to better understand how human metabolism works. What did you learn?

The Hadza, to this day, don't have any domesticated crops or animals or machines or guns or electricity or anything like that. They live in grass houses in the open savanna in northern Tanzania. And every morning they wake up and women are off to get plant foods, such as berries and tubers. The men go off to hunt for a wild game using bow and arrow.

For somebody like me who studies how humans evolved, a community like that is just an invaluable way to ask what hunting and gathering does to our bodies. Because we humans evolved over millennia as a hunting and gathering species. And yes in a population like that, food can be scarce sometimes. And you're always spending lots of energy on physical activity. So your body really has to be good at prioritizing how it spends its calories.

The Hadza walk everywhere they go, and compared to us, are seldom sedentary. I'd assume they burn significantly more calories than we do in a day. Yet surprisingly, your work shows that their metabolism isn't all that different from the average American.

About 10 years ago, we went and measured how many calories men and women in the Hadza community burn every day. The Hadza are so physically active, we'd expect that their total calories burned every day would be much higher than we see in the U.S. and Europe and other industrialized populations. And instead, what we found was that actually, even though men are getting 19,000 steps today, women are getting 13,000 steps a day on top of all the other work they do, they aren't burning more total calories every day than we are in the West.

Physical activity ends up being another one of those things that the body can juggle and adjust. And so in the same way that your body can adjust to changes in your food environment, your body can adjust to changes in your physical activity. So for the Hadza, their "metabolic business" has adjusted so that they spend less on other body systems to make room for that big physical activity workload that they have.

What does this mean for someone who is trying to lose weight today?

If you or I started an exercise program tomorrow, we will burn extra calories from that exercise for a while. But after a couple of months, our bodies will adjust so that we're spending about the same energy every day as we were before we started the exercise. Your body adjusts how it spends its energy to keep the total calories burned every day within a relatively narrow range. It just speaks to how adaptable and flexible our bodies are and how we're not really in charge of our metabolisms the way we think.

You include a section in the book about the TV show The Biggest Loser in which contestants competed to see who could lose the most weight. What was the problem with that?

Contestants went on this show and were put under a brutal routine of intense exercise, coupled with near starvation. You can lose a lot of weight that way. But it's not sustainable. Your body pushes back hard by slashing its metabolic rate. Some of those contestants have been followed for years afterward. The folks that have been able to keep the weight off still have lowered metabolic rates from what they went through. A lot of the contestants gained the weight back.

It goes to show you the way to fix the obesity crisis societally or [to lose and keep weight off] individually is not some big, drastic crash approach. You've got to go more sustainably than that because the body will just push back if you push too hard.

So if your goal is to lose weight, nutrition will offer the bigger impact than exercise. But for maintenance of healthy weight, that's where exercise is essential?

That's right. Let's rethink what exercise is doing. I call it the rhythm section of your body. Exercise keeps everything on the same page, on the same beat, and it helps regulate how your body works. And so once you get to a healthier weight, once you are able to lose weight and get to a set point where you want to be, exercise is really key in keeping yourself there. Exercise changes the way that your body regulates how hungry you feel or how full you feel.

The paleo diet is based on the idea that when we were all hunter-gatherers, we ate a certain way, and we didn't have problems with obesity or Type 2 diabetes or high blood pressure. But based on your study of the Hadza, what is it that the paleo folks get wrong?

If you go out and have a chance to live with a group like the Hadza, you realize that a lot of the stories we tell ourselves about the past, including things like the paleo diet, just kind of fall apart. So there's this idea in the paleo diet world that there's one sort of single natural human diet, and that diet was very meat heavy, hardly any carbs at all and certainly no sugars.

[In reality] the Hadza have a mix of plants and animals in their diets. It changes day to day and year to year, but about half of the calories are coming from plants. And not only that but actually something like 10[%] to 20% of their calories every day comes from wild honey, which is just sugar and water, you know, which it would not be on any paleo diet person's menu. Another big part of their diet is the starchy tubers and these root vegetables, which you often aren't allowed to eat on some version of the paleo diet.

One last thing that stunned me from your book: You write about the metabolic cost of pregnancy comparing pregnant women to Tour de France riders.

You can push the body as in the Tour de France, where riders burn 7,000 or 8,000 calories a day for three weeks. But it also makes sense that pregnancy is pushing the same metabolic limits as something like the Tour de France. They both run your body's metabolic machinery at full blast for as long as it can keep it up. It just speaks to how taxing pregnancy is, for one thing, but it also speaks to how these things are all connected. Our energetic machinery gets co-opted into these different tasks and makes connections that unite all of these different experiences.

View post:
How Humans Really Burn Calories And What That Means For Losing Weight : Shots - Health News - NPR

Posted in Testosterone Shots | Comments Off on How Humans Really Burn Calories And What That Means For Losing Weight : Shots – Health News – NPR

deCODE genetics – New study on inheritance and fetal growth USA – PRNewswire

Posted: July 21, 2021 at 2:34 am

A total of 243 fetal growth variants are reported and 141 of them were grouped into four main clusters based on separating the effect of the variant on birth weight though the maternal versus fetal genome. The majority of variants show an effect only in the fetus and a quarter of those show evidence of a parent-of-origin specific effect on birth weight i.e. the effect on the fetus differs depending on whether the child inherited the variant from the mother or the father. Some variants have an effect only in the mother but around 30% affect birth weight both through the maternal and fetal genomes, where for some the effect is in the same direction, no matter whether from mother or father, while for others the effect is in opposite directions.

Polygenic risk score analysis of disease-associated variants revealed that variants associating with blood pressure do not associate with birth weight when in the maternal genome but in the fetal genome the blood pressure raising allele correlates with lower birth weight. Variants that associate with risk of type 2 diabetes associate with birth weight through both the maternal and fetal genomes but in opposite directions. In the mother, the risk alleles correlate with higher birth weight but when in the fetus they correlate with lower birth weight.

"The ability to analyse directly the effect of each of the transmitted alleles and the maternal non-transmitted allele allows us to separate what happens through the mother from a direct effect on birth weight through the fetal genome," says Valgerdur Steinthorsdottir scientist atdeCODE Geneticsandauthor on the paper.

The study reports an expanded GWAS meta-analysis of 400,000 children, 270,000 mothers and 60,000 fathers, combining data from the Icelandic Birth Register for 125,000 newborns and their parents with public summary level fetal growth data on children and mothers from the Early Growth Genetics Consortium and UK Biobank. The effects of the fetal, maternal and paternal genomes on birth weight were analysed and the study further includes analysis of birth length and ponderal index.

"It is clear from these results that in our beginnings we are not only shaped by the half of our maternal genome that is transmitted to us but also the untransmitted half," says Kari Stefansson CEO of deCODE genetics. "Here we show how the influence of the two halves can be separated."

Based inReykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using its unique expertise in human genetics combined with growing expertise in transcriptomics and population proteomics and vast amount of phenotypic data, deCODE has discovered risk factors for dozens of common diseases and provided key insights into their pathogenesis. The purpose of understanding the genetics of disease is to use that information to create new means of diagnosing, treating and preventing disease. deCODE is a wholly-owned subsidiary of Amgen (NASDAQ: AMGN).

Video - https://mma.prnewswire.com/media/1557521/Birth_Weight.mp4Photo- https://mma.prnewswire.com/media/1557444/Authors_on_the_paper.jpgLogo - https://mma.prnewswire.com/media/1535464/deCODE_genetics_Amgen_Logo.jpg

SOURCE deCODE genetics

Original post:
deCODE genetics - New study on inheritance and fetal growth USA - PRNewswire

Posted in Genetics | Comments Off on deCODE genetics – New study on inheritance and fetal growth USA – PRNewswire

Why Shares of Fulgent Genetics Rose 77% in the First Half of 2021 – Motley Fool

Posted: July 21, 2021 at 2:34 am

What happened

Shares of Fulgent Genetics (NASDAQ:FLGT) climbed 77% through the first half of 2021, according to data from S&P Global Market Intelligence. The rise was due to the incredible numbers of COVID tests the company was able to run and the customers it was able to line up.

FLGT data by YCharts.

Prior to a broad market sell-off in February, shares of Fulgent had been up more than 250% for the year. As vaccination rates climbed and the need for testing seemed to be waning, the stock collapsed almost 65%. Now that the delta variant of the coronavirus is taking hold, it appears investors are once again jumping on the bandwagon.

Image source: Getty Images.

The volatility obscures a business that has been consistently growing its revenue while demonstrating amazing operating leverage since early in the pandemic. Its core business -- genetic testing -- suffered when doctors' offices and clinics were closing last year, but it has more than fully recovered. Management expects that segment to grow 174% in 2021. Some of the recovery is thanks to being awarded a contract from the Centers for Disease Control and Prevention (CDC) to track COVID through genome sequencing. Still, COVID testing volume is likely to drive the stock price for the remainder of this year.

That's good news for shareholders as cases of the virus have more than doubled in the past two weeks and are up close to 300% over the last month. The company has plenty of capacity. In 2020, Fulgent did 230 times more tests than in the prior year. It managed that increase while still delivering rapid turnaround times to several large counties including Los Angeles and Miami-Dade, as well as the New York City public school system. To top it off, the company's profit margins expanded much faster than revenue, and it has guided for $12 in earnings per share this year on the back of 97% sales growth.

If its partnerships with corporations, large school districts, counties, and the CDC can keep testing volume high, shareholders could get a second half of the year that mirrors the first. Add in potential deals with insurance companies to cover testing and growth for the $2.5 billion company could just be getting started.

This article represents the opinion of the writer, who may disagree with the official recommendation position of a Motley Fool premium advisory service. Were motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Visit link:
Why Shares of Fulgent Genetics Rose 77% in the First Half of 2021 - Motley Fool

Posted in Genetics | Comments Off on Why Shares of Fulgent Genetics Rose 77% in the First Half of 2021 – Motley Fool

SMD – Genetics study in Pakistani and Bangladeshi communities will take action on health inequality – QMUL

Posted: July 21, 2021 at 2:34 am

Published on:

People of Bangladeshi and Pakistani origin have some of the highest rates of heart disease, type 2 diabetes and poor health in the UK.Social Action for Health (SAfH), a health inequality and community development charity, wants people to act to change this.

SAfH are working with Queen Mary University of London to promote the biggest study in the world researching genetics in people of Bangladeshi and Pakistani heritage. With the tagline #OurGenesOurHealth, they hope that British Bangladeshi and Pakistani people can be part of the movement making medical studies representative of those that will benefit most.

The research study, Genes & Health, aims to help fight against major diseases and SAfH are raising awareness of the study and encouraging people to take part. Genes & Health are hoping to get the attention of British Pakistanis and Bangladeshis by sharing a video they have produced with the help of members of the local Pakistani, Bangladeshi communities and Centre of the Cell Youth Membership Forum.

The video features children filmed in their own homes highlighting the diseases they are more at risk of developing and making a plea to their community to give five minutes of their time to provide a once in a lifetime saliva sample and fill in a short form to help change their future. This will contribute to breaking the cycle of health inequality, improving medications and treatment and increasing representation of these groups in medical research improving health and life chances for future generations.

Resarch made possible by Genes & Health volunteers is already making a difference. For example, data from Genes & Health hashelped show that one of the reasons some British Bangladeshi and British Pakistani people have very severe covid-19 is because an inherited genetic risk factor is 4 times more common in the South Asian community.

By volunteering this Eid and beyond, British Pakistani and Bangladeshi can join almost 50,000 people already signed up to give the gift (#GiveAGiftForEid) of a saliva sample to improve their communitys representation in a health research.

A further 50,000 people are needed, so the team is asking people 16 and over, who are of Bangladeshi, British-Bangladeshi, Pakistani or British-Pakistani heritage, to donate a saliva sample. For more information, or to take part, click here.

Dr Sarah Finer at Queen Mary University of London, said: As a doctor and researcher working in east London, I see the huge impact of conditions such as type 2 diabetes, heart disease and depression have on British Bangladeshis and Pakistanis. There is an urgent need to better understand the causes and consequences of ill health in these communities who are disproportionately affected by health conditions and under-represented in many research studies.

Genes & Health is a unique programme of research, focusing on health and disease in British Bangladeshis and Pakistanis. It brings together a network of world-class researchers who are making important new discoveries, including on COVID-19, type 2 diabetes, heart disease and the development of new medicines. Genes & Health research will have a big impact on health and disease in the long-term, and will help redress inequalities that exist currently. Genes & Health thanks the almost 50,000 volunteers who have helped make it a success so far and looks forward to many new volunteers joining us this Eid.

CeriDurham, CEO at SAFH, said: Social Action for Healths mission is to work alongside diverse communities in East London and inspire them to take action to live healthier lives. We believe that by people engaging with this research, not only will health inequalities be addressed, but it will inspire more medical studies to engage with a more diverse and representative group of beneficiaries.

The parents of these children wanted to be involved in making this video because they want a better, healthier future for themselves and their communities. They have something important to say and we should all be listening. We've had very positive feedback from parents, who are committed to tackling health inequalities as much as we are.

Farah, a parent of two children who took part in the video, said: Its heart-breaking to see that from one generation to the next we are carrying conditions like diabetes with us. This needs to stop. This impactful video shows how our innocent children may in the future suffer from these medical conditions when they can be prevented.

We hope that the shock tactic our video has will wake up the South Asian community into taking positive action and this is why my children agreed to take part and why I wanted them to be in this campaign. This isnt all about us, its about the future of our children and grandchildren."

The study is funded by the Wellcome Trust and Barts Charity, sponsored by Queen Mary University of London, and reviewed and approved by London South East National Research Ethics Service Committee.

See original here:
SMD - Genetics study in Pakistani and Bangladeshi communities will take action on health inequality - QMUL

Posted in Genetics | Comments Off on SMD – Genetics study in Pakistani and Bangladeshi communities will take action on health inequality – QMUL